NUWELLIS INC (NUWE)
US67113Y6032 - Common Stock
We assign a fundamental rating of 2 out of 10 to NUWE. NUWE was compared to 188 industry peers in the Health Care Equipment & Supplies industry. NUWE may be in some trouble as it scores bad on both profitability and health. NUWE is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year NUWE has reported negative net income.
NUWE had a negative operating cash flow in the past year.
NUWE had negative earnings in each of the past 5 years.
In the past 5 years NUWE always reported negative operating cash flow.
1.2 Ratios
NUWE has a worse Return On Assets (-368.57%) than 96.26% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -368.57% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-118.33%
ROA(5y)-169.36%
ROE(3y)-299.28%
ROE(5y)-428.46%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 60.29%, NUWE is in line with its industry, outperforming 58.29% of the companies in the same industry.
In the last couple of years the Gross Margin of NUWE has grown nicely.
The Profit Margin and Operating Margin are not available for NUWE so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 60.29% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1%
GM growth 5Y16.14%
2. Health
2.1 Basic Checks
NUWE does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for NUWE has been reduced compared to 1 year ago.
Compared to 5 years ago, NUWE has more shares outstanding
NUWE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
NUWE has an Altman-Z score of -73.43. This is a bad value and indicates that NUWE is not financially healthy and even has some risk of bankruptcy.
NUWE's Altman-Z score of -73.43 is on the low side compared to the rest of the industry. NUWE is outperformed by 93.58% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -73.43 |
ROIC/WACCN/A
WACC9%
2.3 Liquidity
NUWE has a Current Ratio of 1.20. This is a normal value and indicates that NUWE is financially healthy and should not expect problems in meeting its short term obligations.
NUWE has a Current ratio of 1.20. This is amonst the worse of the industry: NUWE underperforms 87.17% of its industry peers.
NUWE has a Quick Ratio of 1.20. This is a bad value and indicates that NUWE is not financially healthy enough and could expect problems in meeting its short term obligations.
NUWE has a worse Quick ratio (0.71) than 91.44% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.2 | ||
| Quick Ratio | 0.71 |
3. Growth
3.1 Past
NUWE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 91.23%, which is quite impressive.
Looking at the last year, NUWE shows a quite strong growth in Revenue. The Revenue has grown by 8.32% in the last year.
The Revenue has been growing by 12.13% on average over the past years. This is quite good.
EPS 1Y (TTM)91.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.24%
Revenue 1Y (TTM)8.32%
Revenue growth 3Y6.01%
Revenue growth 5Y12.13%
Sales Q2Q%5.73%
3.2 Future
Based on estimates for the next years, NUWE will show a very strong growth in Earnings Per Share. The EPS will grow by 25.92% on average per year.
The Revenue is expected to grow by 23.98% on average over the next years. This is a very strong growth
EPS Next Y94.03%
EPS Next 2Y41.21%
EPS Next 3Y25.92%
EPS Next 5YN/A
Revenue Next Year1.23%
Revenue Next 2Y9.11%
Revenue Next 3Y23.98%
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
NUWE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NUWE. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as NUWE's earnings are expected to grow with 25.92% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.21%
EPS Next 3Y25.92%
5. Dividend
5.1 Amount
No dividends for NUWE!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NUWELLIS INC
NASDAQ:NUWE (11/21/2024, 2:10:27 PM)
1.2096
-0.09 (-6.95%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.26M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -368.57% | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 60.29% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover1.46
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.2 | ||
| Quick Ratio | 0.71 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)91.23%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y94.03%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)8.32%
Revenue growth 3Y6.01%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y